Pharmabiz1d
Merus’ petosemtamab receives US FDA breakthrough therapy designation for 1L PD-L1 positive head and neck squamous cell carcinoma
Utrecht, The Netherlands Thursday, February 20, 2025, 15:00 Hrs [IST] ...
Oncology Nurse Advisor2d
Esophageal Squamous Cell Carcinoma Survival Trends Show Demographic Disparities
Researchers evaluated demographic characteristics associated with survival trends in patients with squamous cell carcinoma of the upper esophagus.
Discovery reveals key protein that helps squamous cell carcinoma resist ferroptosis
A research team led by Prof. Jiang Yanyi from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences has uncovered an important mechanism that enables squamous cell carcinoma (SCC ...
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...
BioWorld4d
KAT8 inhibition as therapeutic strategy for esophageal cancer
Researchers from Zhengzhou University and affiliated organizations published data from a study that aimed to assess the expression levels of histone modifier enzymes in esophageal squamous cell ...